



Multi-site Gram-Negative Surveillance Initiative (MuGSI)

CRE NDM and KPC treatment data collection form

State ID: _____ Patient ID: _____ Collection Date: ____/____/____ Date of incident specimen collection : ____/____/____

1. Antibiotic (brand)	2a. Administered to treat CRE	3a. Start Date	3b. Stop Date	3c. Start Date	3d. Stop Date	3e. Start Date	3f. Stop Date	3g. Treatment continued after hospital discharge
Amikacin (Amikin)	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Aztreonam (Azactam)	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Aztreonam-avibactam	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Cefepime (Maxipime)	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Cefiderocol	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Ceftriaxone (Rocephin)	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Cefotaxime (Claforan)	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Ceftazidime (Fortaz)	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Ceftazidime-avibactam	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No ☐ Unknown
Ceftolozane-tazobactam	☐ Yes ☐ No ☐ Unknown	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	____/____/____	☐ Yes ☐ No

								☐ Unknown
Ciprofloxacin (Cipro)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Colistin or Polymyxin E (Coly-Mycin-S)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Cefepime-enmetazobactam	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Doripenem (Doribax)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Doxycycline	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Eravacycline	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Ertapenem (Invanz)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Fosfomycin (Monurol)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Gentamicin (Garamycin)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Imipenem (Primaxin)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Imipenem-relebactam	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Levofloxacin (Levaquin)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Meropenem (Merrem)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown

Meropenem-vaborbactam	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Minocycline	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Nitrofurantoin	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Moxifloxacin (Avelox)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Piperacillin-Tazobactam (Zosyn)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Plazomicin	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Polymixin B	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Tigecycline (Tygacil)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Trimetoprim-sulfamethoxazole	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Tobramycin (Nebcin)	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Other_____	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Other_____	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
Other_____	☐ Yes ☐ No ☐ Unknown	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	<u> / / </u>	☐ Yes ☐ No ☐ Unknown
	☐ Yes ☐ No							☐ Yes

4a. Was ID consulted for the treatment of the CRE infection? ☐ Yes ☐ No ☐ Unknown		4b. If Yes, report date of initial ID consult (or reconsult) ____ / ____ / ____	
4c. Were there any antibiotics noted by a clinician that could not be used for CRE treatment because they were not available or not on formulary? ☐ Yes ☐ No ☐ Unknown 4d. If Yes, please specify antibiotics _____			
Testing for carbapenemase genes: ☐ No testing for carbapenemase gene data available from the medical record			
5a. Was the incident specimen tested for carbapenemase genes? ☐ Yes ☐ No ☐ Unknown		5b. If yes, what testing method was used? (check all that apply) ☐ Automated Molecular Assay ☐ Carba-R ☐ Check Points ☐ Immunochromatographic lateral flow tests (ICT) ☐ MALDI-TOF MS ☐ Next Generation Nucleic Acid Sequencing ☐ PCR ☐ Streck ARM-D ☐ Other (specify): _____ ☐ Unknown	
		5c. If yes, dates of testing ____ / ____ / ____ ____ / ____ / ____	
		5d. If tested, what was the testing result? ☐ NDM ☐ Pos ☐ Neg ☐ Ind ☐ Unk ☐ KPC ☐ Pos ☐ Neg ☐ Ind ☐ Unk _____	
Parameters to calculate qPitt Bacteremia score: Record the measurements that occurred within 48 hours before or on the day of the DISC.			
6a. Highest body temperature (F or °C) on the day of the DISC _____ F _____ °C		6b. Lowest body temperature (F or °C) on the day of the DISC _____ F _____ °C	
		6c. Has the patient had an acute hypotensive event with drop in systolic blood pressure >30 mm Hg and diastolic blood pressure >20 mm Hg on the day of the DISC? ☐ Yes ☐ No ☐ Unknown	
6d. Systolic blood pressure (lowest value) on the day of the DISC _____ mm Hg		6e. Is the patient receiving mechanical ventilation on the day of the DISC? ☐ Yes ☐ No ☐ Unknown	
6g. Has the patient had a cardiac arrest on the day of the DISC or within 48 hours before the DISC? ☐ Yes ☐ No ☐ Unknown		6h. Is the patient receiving intravenous vasopressors (medications to help raise blood pressure) on the day of the DISC? ☐ Yes ☐ No ☐ Unknown	
		6i. Mental state on the day of the DISC (check all that apply) ☐ Alert (normal) ☐ Disoriented ☐ Stuporous ☐ Comatose ☐ Sedated ☐ Unknown	

7a. Susceptibility results (AST) from the medical record:						
Please complete the table based on the information found in the medical record ☐ No susceptibility data available from the medical record						
Antibiotic (brand)	MIC or zone diameter (clinical lab)	Interpretation (clinical lab)	AST result date (clinical lab)	MIC or zone diameter (SPHL/ARLN)	Interpretation (SPHL/ ARLN)	AST result date (SPHL/ARLN)
Amikacin (Amikin)						
Aztreonam (Azactam)						
Aztreonam-avibactam						
Cefepime (Maxipime)						
Cefiderocol						
Ceftriaxone (Rocephin)						
Cefotaxime (Claforan)						
Ceftazidime (Fortaz)						
Ceftazidime-avibactam						
Ceftolozane-tazobactam						
Ciprofloxacin (Cipro)						
Colistin or Polymyxin E (Coly-Mycin-S)						
Cefepime- enmetazobactam						
Doripenem (Doribax)						
Doxycycline						
Eravacycline						
Ertapenem (Invanz)						
Fosfomycin (Monurol)						
Gentamicin (Garamycin)						
Imipenem (Primaxin)						
Imipenem-relebactam						
Levofloxacin (Levaquin)						
Meropenem (Merrem)						
Meropenem-vaborbactam						
Minocycline						
Nitrofurantoin						
Moxifloxacin (Avelox)						
Piperacillin- Tazobactam (Zosyn)						
Plazomicin						
Polymixin B						
Tigecycline (Tygacil)						
Trimetoprim- sulfamethoxazole						
Tobramycin (Nebcin)						
Other _____						

7b. Susceptibility results from the ET, KB, MS, PX, SEN, VK, APS data sources in lab reports:

Please complete the table based on the information found at laboratory reports received by EIP sites (if not available or different from results in the medical record)

Antibiotic (brand)	MIC or zone diameter (clinical lab)	Interpretation (clinical lab)	AST result date (clinical lab)	MIC or zone diameter (SPHL/ARLN)	Interpretation (SPHL/ ARLN)	AST result date (SPHL/ARLN)
Amikacin (Amikin)						
Aztreonam (Azactam)						
Aztreonam-avibactam						
Cefepime (Maxipime)						
Cefiderocol						
Ceftriaxone (Rocephin)						
Cefotaxime (Claforan)						
Ceftazidime (Fortaz)						
Ceftazidime-avibactam						
Ceftolozane-tazobactam						
Ciprofloxacin (Cipro)						
Colistin or Polymyxin E (Coly-Mycin-S)						
Cefepime- enmetazobactam						
Doripenem (Doribax)						
Doxycycline						
Eravacycline						
Ertapenem (Invanz)						
Fosfomycin (Monurol)						
Gentamicin (Garamycin)						
Imipenem (Primaxin)						
Imipenem-relebactam						
Levofloxacin (Levaquin)						
Meropenem (Merrem)						
Meropenem-vaborbactam						
Minocycline						
Nitrofurantoin						
Moxifloxacin (Avelox)						
Piperacillin- Tazobactam (Zosyn)						
Plazomicin						
Polymixin B						
Tigecycline (Tygacil)						
Trimetoprim- sulfamethoxazole						
Tobramycin (Nebcin)						
Other _____						

8. Form completion status ☐ Complete ☐ Pending	9. Date of abstraction ____/____/____	10. SO initials
11. Comments		